Tumor suppression by p53 without accelerated aging: Just enough of a good thing?

Cell Cycle

Volumn 5, Issue 7, 2006, Pages 714-717

  Mendrysa, Susan M ^a   Perry, Mary Ellen ^b,c  

^a PURDUE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Aging; Cancer therapy; Chemoprevention; Mdm2; p53; Tumor suppression

Indexed keywords

PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDM2 INHIBITOR; PROTEIN P53; REGULATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AGING; ANIMAL EMBRYO; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; DRUG TARGETING; EXPERIMENTAL MOUSE; FAMILIAL CANCER; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ENGINEERING; GENETIC SUSCEPTIBILITY; HUMAN; IONIZING RADIATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATOR GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ANIMALIA; MURINAE;

EID: 33645711615     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.7.2632     Document Type: Review

References (33)

1. Jones SJ, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in MDM2-deficient mice by absence of p53. Nature 1995; 378:206-208.
2. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378:203-206.
3. Parant J, Chavez-Reves A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genet 2001; 29:92-95.
4. Westphal CH, Hoyes KP, Canman CE, Huang X, Kastan MB, Hendry JH, Leder P. Loss of atm radisensitizes multiple p53 null tissues. Cancer Res 1998; 58:5637-5639.
5. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME. Mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing radiation. Mol Cell Biol 2003; 23:462-473.
6. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Park SH, Thompson T, Karsenty, G, Bradley A, Donehower L. P53 mutant mice that display early ageing-associated phenotypes. Nature 2002; 415:45-53.
7. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thorner M, Scrable H. Modulation of mammalian life span by the short isoform of p53. Genes & Dev 2004; 18:306-319.
8. Van Heemst D, Mooijaart, SP, Beekman M, Schreuder J., de Craen AJM, Brandt BW, Slagboom PE, Westendorp, RGJ. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontology 2005; 40:11-15.
9. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang, S-J, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602.
10. Swinney RM, Hsu SC, Hirschman BA, Chen TT-C, Tomlinson GE. MDM2 promoter variation and age of diagnosis of acute lymphocytic leukaemia. Leukemia 2005; 19:1996-1998.
11. Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haploinsufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J 2003; 22:1442-1450.
12. Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, Ores M. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Current Cancer Drug Targets 2005; 5:57-68.
13. Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms. Int J of Oncology 2002; 20:745-752.
14. Song E, Zhu P, Lee S-K, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotech 2005; 23:709-717.
15. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LGGC, Masucci M, Pramanik A, Selivanova G. Small molecule RITA bindstop53, blocks p3-HDM-2 interaction and activates p53 function in tumors. Nature Med 2004; 10:1321-1328.
16. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu E. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-848.
17. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao S, Ramachandren K, Bylebyl GR, Zhang M, Manthey CL, Patrella EC, Pantoliano MW, Deckman IC, Spurlino JC, Maroney AC, Tomczuk BE, Molloy CJ, Bone RF. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 2005; 48:909-912.
18. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoi P, Kenten JH, Phillips AC, Weissman AM, Vousden KH. Small molecular inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7:547-559.
19. Mendrysa SM, O'Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA, Perry ME. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 2006; 20:16-21.
20. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990; 247:322-324.
21. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. A senescence program controlled by p53 and p16ink4a contributes to the outcome of cancer therapy. Cell 2002; 109:335-346.
22. Cao L, Li W, Kim S, Brodie SG, Deng C-X. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev 2003; 17:201-213.
23. Lim D-S, Vogel H, Willerford DM, Sands AT, Platt KA, Hasty P. Analysis of ku80-mutant mice and cells with deficient levels of p53. Mol Cell Biol 2000; 20:3772-3780.
24. Sharpless NE, DePinho RA. Telomeres, stem cells senescence and cancer. J Clinical Invest 2004; 113:160-168.
25. Gentry A, Venkatachalam S. Complicating the role of p53 in aging. Aging Cell 2005; 4:157-160.
26. Bauer JH, Poon PC, Glatt-Deeley H, Abrams JM, Helfand SL. Neuronal expression of p53 dominant-negative proteins in adult Drosophila melanogaster extends life span, Curr Biol 2005; 15:2063-2068.
27. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 1989; 9:3982-3991.
28. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM, Weill JC, Blasco MA, Serrano M. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 2002; 21:6225-6235.
29. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20:267-275.
30. Holzenberger, M. The role of insulin-like signalling in the regulation of ageing. Horm Res 2004; 62 Suppl 1:89-92.
31. Keyes WM, Wu Y, Vogel H, Guo X, Lowe S, Mills AA. P63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev 2005; 19:1986-1999.
32. Chao C, Hergenhahn M, Kaeser M.D, Wu Z, Saito S, Iggo R, Hollstein M, Appella E, Xu Y. Cell type- and promoter-specific roles of ser18 phosphorylation in regulating p53. J Biol Chem 2003; 278:41028-41033.
33. Christophorou MA, Martin-Zanca D, Soucek L, Lawler ER, Brown-Swigart L, Verschuren EW, Evan GI. Temporal dissection of p53 function in vitro and in vivo. Nature Genet 2005; 37: 718-726.